Table Info

Table 1.

List of current clinical trials incorporating EUS-RFA into the clinical management of pancreatic adenocarcinoma

Study title for RCT	NCT number	Conditions	Interventions	Location
EUS-RFA for pancreatic neoplasms	NCT03218345	Pancreatic neoplasms	Procedure: EUS-RFA	Hong Kong, China
EUS-RFA for unresectable pancreatic cancer	NCT04310111	PDAC	Procedure: EUS-RFA	China
EUS-RFA for unresectable PDAC	NCT03772756	Pancreatic adenocarcinoma non-resectable	Procedure: EUS guided RFA Radiation: chemoradiotherapy	China
EUS-RFA for treatment of PDAC	NCT05723107	Pancreatic cancer	Drug: chemotherapy Device: EUS-RFA	NY, USA
Evaluation of safety and feasibility of EUS-RFA for solid pancreatic neoplasms	NCT03435770	Pancreatic neoplasms	Device: EUS-RFA needle	Singapore
Evaluation of EUS-RFA for the management of pancreatic tumors, ERASE Study	NCT05961982	Pancreatic neoplasm	Procedure: EUS-guided fine-needle aspiration Procedure: EUS-RFA	Ohio, USA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of EUS-RFA in pancreatic cancer	NCT04990609	PDAC	Device: EUS-RFA Drug: neoadjuvant chemotherapy (NAC)	Houston, USA
EUS-RFA of not-resectable pancreatic cancer	NCT04164992	PDAC	Device: EUSRA electrode needle connected to a radiofrequency generator (VIVA RF Generator; STARmed, Seoul, S. Korea)	Italy
Safety and efficacy of an ablation catheter for the treatment of pancreatic premalignant cyctic lesions	NCT03417843	Pancreatic cancer Pancreatic neuroendocrine tumor Pancreatic Cyst	Device: EUSRA RF electrode	Israel
Trial comparing EUS-RFA vs. EUS-guided celiac plexus neurolysis	NCT03152487	Pancreatic adenocarcinoma Pancreatic neoplasms	Celiac plexus neurolysis RFA	Orlando, USA
EUS-coeliac plexus block vs. RFA in pain relief of patients with malignancy	NCT04809935	Cancer of pancreas Pancreatic neoplasms	Drug: 98% dehydrated alcohol Device: 19 G EUSRA needle, Taewoong Medical, Korea	Hong Kong, China
Efficacy and safety of RFA in pancreatic neuroendocrine and cystic tumor	NCT02330497	Pancreatic tumor Endocrine tumor Neoplasms, cystic, mucinous, and serous	Procedure: RFA under EUS	France
EUS RFA, database repository	NCT04693754	Pancreatic neoplasm	Procedure: RFA under EUS	Indiana, USA

RCT: randomized clinical trial; EUS-RFA: endoscopic ultrasound-guided radiofrequency ablation; PDAC: pancreatic ductal adenocarcinoma; FNA: fine needle biopsy

Declarations

Author contributions

VM and NCT: Conceptualization. VM, BM, PSH, and JMBL: Data curation, Writing—original draft, Writing—review & editing. All authors review and edit the manuscript for intellectual content and final approval.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

JMB-L and NT are supported by NCI R01 [CA277161]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. [DOI] [PubMed]

Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2024;8:27. [DOI] [PubMed] [PMC]

Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med. 2019;8:2. [DOI] [PubMed] [PMC]

Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46. [DOI] [PubMed]

Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, et al. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Exp Mol Med. 2017;49:e406. [DOI] [PubMed] [PMC]

Yokoyama T, Egami K, Miyamoto M, Watanabe H, Hasegawa H, Iida S, et al. Percutaneous and laparoscopic approaches of radiofrequency ablation treatment for liver cancer. J Hepatobiliary Pancreat Surg. 2003;10:425–7. [DOI] [PubMed]

Song TJ, Seo DW, Lakhtakia S, Reddy N, Oh DW, Park DH, et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016;83:440–3. [DOI] [PubMed]

Goldberg SN, Mallery S, Gazelle GS, Brugge WR. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc. 1999;50:392–401. [DOI] [PubMed]

Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381–91. [DOI] [PubMed] [PMC]

10.

Froelich MF, Schnitzer ML, Rathmann N, Tollens F, Unterrainer M, Rennebaum S, et al. Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. Cancers (Basel). 2021;13:1507. [DOI] [PubMed] [PMC]

11.

Lorber G, Glamore M, Doshi M, Jorda M, Morillo-Burgos G, Leveillee RJ. Long-term oncologic outcomes following radiofrequency ablation with real-time temperature monitoring for T1a renal cell cancer. Urol Oncol. 2014;32:1017–23. [DOI] [PubMed]

12.

Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, et al. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. Liver Cancer. 2020;9:50–62. [DOI] [PubMed] [PMC]

13.

Khoury T, Sbeit W, Napoléon B. Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: A critical review focusing on safety, efficacy and controversies. World J Gastroenterol. 2023;29:157–70. [DOI] [PubMed] [PMC]

14.

Kongkam P, Tiankanon K, Seo DW, Luangsukrerk T, Sriuranpong V, Nantavithya C, et al. EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observational open-label pilot study. Endosc Ultrasound. 2023;12:402–8. [DOI] [PubMed] [PMC]

15.

Karaisz FG, Elkelany OO, Davies B, Lozanski G, Krishna SG. A Review on Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of Pancreatic Lesions. Diagnostics (Basel). 2023;13:536. [DOI] [PubMed] [PMC]

16.

Picchi SG, Lassandro G, Bianco A, Coppola A, Ierardi AM, Rossi UG, et al. RFA of primary and metastatic lung tumors: long-term results. Med Oncol. 2020;37:35. [DOI] [PubMed]

17.

Dhar J, Samanta J, Nabi Z, Aggarwal M, Facciorusso A, Conti Bellocchi MC, et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma: a state of the art review. Expert Rev Gastroenterol Hepatol. 2024;18:37–53. [DOI] [PubMed]

18.

Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351–69. [DOI] [PubMed] [PMC]

19.

McGahan JP, Gu WZ, Brock JM, Tesluk H, Jones CD. Hepatic ablation using bipolar radiofrequency electrocautery. Acad Radiol. 1996;3:418–22. [DOI] [PubMed]

20.

Verna EC, Dhar V. Endoscopic ultrasound-guided fine needle injection for cancer therapy: the evolving role of therapeutic endoscopic ultrasound. Therap Adv Gastroenterol. 2008;1:103–9. [DOI] [PubMed] [PMC]

21.

Armellini E, Crinò SF, Ballarè M, Occhipinti P. Endoscopic ultrasound-guided radiofrequency ablation of a pancreatic neuroendocrine tumor. Endoscopy. 2015;47:E600–1. [DOI] [PubMed]

22.

Pai M, Habib N, Senturk H, Lakhtakia S, Reddy N, Cicinnati VR, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg. 2015;7:52–9. [DOI] [PubMed] [PMC]

23.

Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013;398:63–9. [DOI] [PubMed]

24.

Barthet M. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumor. Ann Endocrinol (Paris). 2019;80:182–4. [DOI] [PubMed]

25.

Barthet M, Giovannini M, Lesavre N, Boustiere C, Napoleon B, Koch S, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019;51:836–42. [DOI] [PubMed]

26.

Bang JY, Sutton B, Hawes RH, Varadarajulu S. EUS-guided celiac ganglion radiofrequency ablation versus celiac plexus neurolysis for palliation of pain in pancreatic cancer: a randomized controlled trial (with videos). Gastrointest Endosc. 2019;89:58–66.e3. [DOI] [PubMed]

27.

Scopelliti F, Pea A, Conigliaro R, Butturini G, Frigerio I, Regi P, et al. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Surg Endosc. 2018;32:4022–8. [DOI] [PubMed]

28.

Cazacu IM, Singh BS, Saftoiu A, Bhutani MS. Endoscopic Ultrasound-Guided Treatment of Pancreatic Cancer. Curr Gastroenterol Rep. 2020;22:27. [DOI] [PubMed]

29.

Dhaliwal A, Kolli S, Dhindsa BS, Choa J, Mashiana HS, Ramai D, et al. Efficacy of EUS-RFA in pancreatic tumors: Is it ready for prime time? A systematic review and meta-analysis. Endosc Int Open. 2020;8:E1243–51. [DOI] [PubMed] [PMC]

30.

Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, et al.; Alliance for Clinical Trials on Oncology. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17:505. [DOI] [PubMed] [PMC]

31.

Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505. [DOI] [PubMed] [PMC]

32.

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. [DOI] [PubMed]

33.

Lemdani K, Mignet N, Boudy V, Seguin J, Oujagir E, Bawa O, et al. Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma. Oncoimmunology. 2019;8:1550342. [DOI] [PubMed] [PMC]

34.

Arcidiacono PG, Carrara S, Reni M, Petrone MC, Cappio S, Balzano G, et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc. 2012;76:1142–51. [DOI] [PubMed]

35.

Crinò SF, D’Onofrio M, Bernardoni L, Frulloni L, Iannelli M, Malleo G, et al. EUS-guided Radiofrequency Ablation (EUS-RFA) of Solid Pancreatic Neoplasm Using an 18-gauge Needle Electrode: Feasibility, Safety, and Technical Success. J Gastrointestin Liver Dis. 2018;27:67–72. [DOI] [PubMed]

36.

Oh D, Seo DW, Song TJ, Park DH, Lee SK, Kim MH. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. Endosc Ultrasound. 2022;11:68–74. [DOI] [PubMed] [PMC]

37.

Paiella S, Malleo G, Cataldo I, Gasparini C, De Pastena M, De Marchi G, et al. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Langenbecks Arch Surg. 2018;403:213–20. [DOI] [PubMed]

38.

Thosani N, Cen P, Rowe J, Guha S, Bailey-Lundberg JM, Bhakta D, et al. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for advanced pancreatic and periampullary adenocarcinoma. Sci Rep. 2022;12:16516. [DOI] [PubMed] [PMC]

39.

Wang J, Wang Y, Zhao Y, Wu X, Zhang M, Hou W, et al. Endoscopic ultrasound-guided radiofrequency ablation of unresectable pancreatic cancer with low ablation power and multiple applications: a preliminary study of 11 patients. Ann Palliat Med. 2021;10:1842–50. [DOI] [PubMed]

40.

Fei Q, Pan Y, Lin W, Zhou Y, Yu X, Hou Z, et al. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Cell Death Dis. 2020;11:589. [DOI] [PubMed] [PMC]

41.

Yousaf MN, Ehsan H, Muneeb A, Wahab A, Sana MK, Neupane K, et al. Role of Radiofrequency Ablation in the Management of Unresectable Pancreatic Cancer. Front Med (Lausanne). 2021;7:624997. [DOI] [PubMed] [PMC]

42.

Faraoni EY, O’Brien BJ, Strickland LN, Osborn BK, Mota V, Chaney J, et al. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer. Cancer Immunol Res. 2023;11:4–12. [DOI] [PubMed] [PMC]

43.

Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R. Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. Proc Natl Acad Sci U S A. 2016;113:11300–5. [DOI] [PubMed] [PMC]

44.

Faraoni EY, Strickland LN, O’Brien BJ, Barraza JF, Thosani NC, Wray CJ, et al. Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma. Front Oncol. 2022;12:995027. [DOI] [PubMed] [PMC]

45.

Wu Y, Ma J, Yang X, Nan F, Zhang T, Ji S, et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. 2024;187:1422–39.e24. [DOI] [PubMed]

46.

Shou J, Mo F, Zhang S, Lu L, Han N, Liu L, et al. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy. Front Immunol. 2022;13:1000681. [DOI] [PubMed] [PMC]

47.

Faraoni EY, Ju C, Robson SC, Eltzschig HK, Bailey-Lundberg JM. Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases. Front Physiol. 2022;13:849258. [DOI] [PubMed] [PMC]

48.

Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016;5:e1208875. [DOI] [PubMed] [PMC]

49.

Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, et al. Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014;74:6048–59. [DOI] [PubMed] [PMC]

50.

Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362. [DOI] [PubMed] [PMC]

51.

Linde IL, Prestwood TR, Qiu J, Pilarowski G, Linde MH, Zhang X, et al. Neutrophil-activating therapy for the treatment of cancer. Cancer Cell. 2023;41:356–72.e10. [DOI] [PubMed] [PMC]

52.

Huang X, Nepovimova E, Adam V, Sivak L, Heger Z, Valko M, et al. Neutrophils in Cancer immunotherapy: friends or foes? Mol Cancer. 2024;23:107. [DOI] [PubMed] [PMC]

53.

Hussain SM, Reed LF, Krasnick BA, Miranda-Carboni G, Fields RC, Bi Y, et al. IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma. Sci Rep. 2018;8:5808. [DOI] [PubMed] [PMC]

54.

Li Y, Zhu L, Chu Z, Yang T, Sun HX, Yang F, et al. Characterization and biological significance of IL-23-induced neutrophil polarization. Cell Mol Immunol. 2018;15:518–30. [DOI] [PubMed] [PMC]

55.

Xia C, Yin S, To KKW, Fu L. CD39/CD73/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22:44. [DOI] [PubMed] [PMC]

56.

Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014;4:879–88. [DOI] [PubMed]

57.

Blocking CD73 Can Shrink Pancreatic Tumors. Cancer Discov. 2021;11:OF4. [DOI] [PubMed]

58.

Zhao J, Soto LMS, Wang H, Katz MH, Prakash LR, Kim M, et al. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology. 2021;21:942–9. [DOI] [PubMed] [PMC]

59.

Faraoni EY, Singh K, Chandra V, Le Roux O, Dai Y, Sahin I, et al. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Cancer Res. 2023;83:1111–27. [DOI] [PubMed] [PMC]

60.

Sahin IH, Iacobuzio-Donahue CA, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20:341–59. [DOI] [PubMed] [PMC]

61.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6. [DOI] [PubMed]

62.

Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433–46. [DOI] [PubMed]

63.

Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137:1102–13. [DOI] [PubMed]